Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.  Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a 14-day full dose regimen, preserves C-peptide and increases the percentage of patients requiring very low doses of insulin (< 0.25 U/kg/day) with good glycemic control (glycosylated hemoglobin, or HbA1C < 7%) compared to placebo.  In addition, these analyses revealed that certain subpopulations may be more likely to respond to teplizumab treatment.  These findings also were presented today by Dr. Nicole Sherry (Massachusetts General Hospital for Children) at the annual American Diabetes Association meeting.

Protege is a two-year, randomized, double-blind, placebo-controlled clinical trial, with 513 patients aged 8–35, recently diagnosed with type 1 diabetes, who were enrolled and treated at 83 clinical centers in North America, Europe, Israel, and India. Participants were allocated 2:1:1:1 to receive daily infusions of teplizumab (full dose for 14 days, 1/3 dose for 14 days, or full dose for 6 days) or placebo at baseline and at 6 months. The primary composite endpoint of the Protege study was the percentage of patients with insulin use < 0.5 U/kg/day and HbA1C < 6.5% at 1 year.  Although teplizumab was shown to have an acceptable safety profile, the primary endpoint was not achieved, as had been previously announced in a joint communication with Eli Lilly and Company in October 2010.  Protege is ongoing and will complete the 2-year follow-up in 2011.

The peer-reviewed article appearing in The Lancet is titled, "Teplizumab for treatment of type 1 diabetes (Protege study):
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... 31, 2015.  The net loss and the loss from ... $13.0 million, respectively, compared to $10.7 million and $8.8 ... March 31, 2015, Alexza had consolidated cash, cash equivalents, ... "We continue to focus on ways in which ...
(Date:5/6/2015)... May 6, 2015 /CNW/ - Celebrities, bloggers and influencers across ... to spread the important message that melanoma prevention begins with ... Maria Sharapova , Hilary Duff , and parenting author ... out to their networks on Monday to share this poignant ... The David Cornfield Melanoma Fund (DCMF)-producers ...
(Date:5/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2qs6vr/cannulas_market ... "Cannulas Market by Product (Nasal, Arterial, Arthroscopy, Ophthalmic, ... (Plastic, Metal) & End Users (Hospitals, Ambulatory Surgical ... to their offering. The global cannulas ... of 5.6% from 2015 to 2020 to reach ...
Breaking Medicine Technology:Alexza Reports 2015 First Quarter Financial Results 2Alexza Reports 2015 First Quarter Financial Results 3Alexza Reports 2015 First Quarter Financial Results 4Alexza Reports 2015 First Quarter Financial Results 5Alexza Reports 2015 First Quarter Financial Results 6Alexza Reports 2015 First Quarter Financial Results 7Alexza Reports 2015 First Quarter Financial Results 8Alexza Reports 2015 First Quarter Financial Results 9Alexza Reports 2015 First Quarter Financial Results 10Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3
... Concert Medical, LLC today announced the launch of ... These guidewires are designed to address an extensive range of coronary ... clearance for the use and sale in the U.S. of the ... is located in Norwell, Mass. and manufactures all ...
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Nabumetone Tablets USP, 500 mg and 750 mg. The ... equivalent to Nabumetone Tablets, a treatment for osteoarthritis and ...
Cached Medicine Technology:Concert Medical Launches 'Conductor™' Family of Interventional Coronary Guidewires 2Concert Medical Launches 'Conductor™' Family of Interventional Coronary Guidewires 3Mylan Receives Approval for Nabumetone Tablets 2
(Date:5/6/2015)... RPS Revolution - a game for the ... true Rock Paper Scissors game - is now taking ... storytelling and easy to learn rules from Rock Paper Scissors, ... favorite. RPS Revolution takes the best parts of ... are grouped in set of three called Trios. Trios like ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 MJNational LLC ... Mobile, (OTC: LGBI), Canna Bizcard ™ platform. This exciting ... in Investor Relations, Product Sales / Services. Now ... bring national awareness to products, services and ticker symbol ... marketing system. , MJNational LLC will provide managed support ...
(Date:5/6/2015)... 2015 Imprivata ® (NYSE: IMPR), ... David Ting will lead a discussion about the Internet ... and user authentication challenges, during Citrix Synergy ... focus on the benefits of creating a network of ... and patients can share information. It will also emphasize ...
(Date:5/6/2015)... May 06, 2015 On April 27, ... Plastic Surgery ,” compiled quotes about cosmetic surgery ... Aniston, pop singer Iggy Azalea, and Gwyneth Paltrow. For ... about having plastic surgery themselves; only a ... and its expectations of youth and beauty. (see: goo.gl/wSomih) ...
(Date:5/6/2015)... May 06, 2015 Qushanna Doby (20) was ... nearby drug treatment center in Florida while under the influence ... 4th. New surveillance tapes released by CBS4’s Peter D’Oench records ... baby. Doby’s child is around one year old. The drug ... shivering outside was not named. The residents polled by CBS ...
Breaking Medicine News(10 mins):Health News:RPS Revolution Launches Kickstarter Campaign 2Health News:RPS Revolution Launches Kickstarter Campaign 3Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 2Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 3Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2
... , , MISSION VIEJO, Calif., Sept. ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative ... of Directors has declared a quarterly cash dividend of $0.045 per ... 2009 to shareholders of record as of September 30, 2009. Ensign ...
... BOTHELL, Wash., Sept. 18 SCOLR Pharma, Inc. ... September 15, 2009, the NYSE Amex LLC (the "Exchange") accepted ... disclosed listing deficiency as set forth in Section 1003(a)(iii) of ... Company,s failure to maintain stockholder,s equity of at least $6,000,000 ...
... , , LAWRENCE, Mass., Sept. ... leading manufacturer of innovative dialysis products, today announced that home dialysis ... Road Trip" with the NxStage(R) System One(TM). As a portable ... opportunity to fit hemodialysis therapy into his own lifestyle and schedule. ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President of ... Andy Stern, President of the Service Employees International Union, ... extremists to silence working families by attacking progressive individuals and community ... of profound change for this country -- from kitchen tables to ...
... , , HAYWARD, Calif., Sept. ... global leader in the medical aesthetics market, today announced that it ... on Tuesday, September 29, 2009 at the Grand Hyatt New York ... for 10:30 a.m. Eastern Time on September 29, 2009. Stephen ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... an immunometric ('sandwich') EIA for the ... serum or plasma. LH in the ... anti-LH antibodies directed at different epitopes. ... particles and the other is labelled ...
Medicine Products: